Document Detail


Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
MedLine Citation:
PMID:  14962259     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Allogeneic transplantation may offer a curative approach to multiple myeloma (MM). We retrospectively analyzed the outcome of patients with multiple myeloma undergoing allogeneic stem cell transplantation in the context of beta(2) microglobulin and chromosome 13q. METHODS: All 13 patients with MM, who were referred to our center for allogeneic stem cell transplantation, were evaluated. Median age of patients was 38 yr, eight patients had chemo-sensitive disease, and median time between diagnosis of MM and transplantation was 15 months. Engraftment, acute and chronic graft vs. host disease, response to treatment, disease-free survival, and overall survival were evaluated according to standard criteria. RESULTS: There was one transplant-related death. Among 12 evaluable patients, seven patients (58%) achieved a complete remission (CR), and four patients (33%) achieved a partial remission. Acute graft vs. host disease occurred in 46% of patients, and chronic graft vs. host disease in 42% of available patients. After a median follow-up of 69.5 months (range, 5-128) nine patients (70%) are still alive, and six of them have remained progression free. Among five patients with low beta(2) microglobulin and normal chromosome 13q, four patients achieved a CR, with CR duration >5 yr in three of them. Among seven patients with elevated ss(2) microglobulin and/or deletion of chromosome 13q, only three CR were observed, with two patients still in CR on days +920 and +161, respectively. CONCLUSIONS: Allogeneic stem cell transplantation in patients with MM results in promising rates of CR, but durable remissions are predominantly seen in patients with favorable prognostic parameters.
Authors:
Werner Rabitsch; Erika Prinz; Jutta Ackermann; Stefan Wöhrer; Hannes Kaufmann; Sonja Seidl; Felix Keil; Peter Kalhs; Hildegard Greinix; Heinz Gisslinger; Gerda Leitner; Johannes Drach
Related Documents :
8136289 - Clonal chromosomal abnormalities in fanconi's anaemia: what do they really mean?
8609709 - Karyotypic evolution in cll: identification of a new sub-group of patients with deletio...
2673329 - Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations.
17353179 - Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping:...
7854769 - Intracellular glutathione content in leukemias.
3605079 - Chronic lymphocytic leukemia in china.
24251769 - Ldl-c linked snps are associated with ldl-c and myocardial infarction despite lipid-low...
9677159 - Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic e...
16154679 - Reducing no flow times during automated external defibrillation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  72     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-02-13     Completed Date:  2004-03-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  26-31     Citation Subset:  IM    
Affiliation:
Bone Marrow Transplantation Unit, Department of Medicine I, University Hospital Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Combined Modality Therapy
Cyclophosphamide / therapeutic use
Disease-Free Survival
Female
Histocompatibility Testing
Humans
Immunosuppressive Agents / therapeutic use
Living Donors
Male
Middle Aged
Multiple Myeloma / drug therapy,  mortality,  pathology,  therapy*
Neoplasm Staging
Retrospective Studies
Stem Cell Transplantation*
Survival Rate
Transplantation Conditioning / methods
Transplantation, Homologous
Whole-Body Irradiation
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations w...
Next Document:  A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patien...